18:32 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Biogen's aducanumab shows continued improvements through 48 weeks in Phase Ib extension for Alzheimer’s

Biogen Inc. (NASDAQ:BIIB) reported additional data from the long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels through 48...
16:51 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented detailed data for BAN2401 that allayed some concerns that the placebo arm had driven a false efficacy signal in the Phase II Study 201 to treat...
23:09 , Oct 25, 2018 |  BC Extra  |  Clinical News

Data raise possibility BAN2401 primarily benefits Alzheimer’s subgroup

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented detailed data for BAN2401 Thursday that allayed some concerns that the placebo arm had driven a false efficacy signal in the Phase II Study 201 to...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
16:46 , Feb 17, 2017 |  BC Week In Review  |  Company News

Incyte sales and marketing update

The U.K.'s NICE issued draft guidance recommending the use of Iclusig ponatinib from Incyte in specific patients with chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). NICE recommends treatment in adult...
22:47 , Feb 8, 2017 |  BC Week In Review  |  Clinical News

Brigatinib regulatory update

Ariad submitted an MAA to EMA for brigatinib to treat metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in adults who have been previously treated with Xalkori crizotinib. The MAA is based on...
02:02 , Jan 14, 2017 |  BioCentury  |  Strategy

Solidifying Takeda’s position

Takeda Pharmaceutical Co. Ltd. ’s proposed acquisition of Ariad Pharmaceuticals Inc. should be the boost the pharma needs to hit $10 billion in cancer sales by 2025, as the biotech’s brigatinib is expected to lead...
01:43 , Jan 14, 2017 |  BioCentury  |  Finance

JPM jump

Nine of the 160 biotechs that presented at the 2017 JPMorgan Healthcare Conference not only skated through the volatile week unharmed, but managed to post gains of at least 15%, with Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)...
19:55 , Jan 13, 2017 |  BC Week In Review  |  Company News

Ariad, Takeda deal

Takeda will acquire cancer company Ariad for $24 per share in cash. Takeda said the deal gives Ariad an enterprise value of about $5.2 billion. The price is a 75% premium to Ariad's close of...
16:22 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

Brigatinib: Updated Ph II ALTA data

Updated data from 110 patients ages ≥18 with locally advanced or metastatic ALK-positive NSCLC whose disease has progressed on Xalkori crizotinib in the open-label, international, pivotal Phase II ALTA trial showed that once-daily 90 mg...